{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:58:21Z","timestamp":1775696301210,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"S23","license":[{"start":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T00:00:00Z","timestamp":1416441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Version 2 of the Collaborative Stage Data Collection System (CSv2) became effective with cases diagnosed in 2010. This report focuses on the CSv2 components required to derive the American Joint Committee on Cancer (AJCC) stage for prostate cancer and on the site\u2010specific factors for prostate cancer captured in CSv2. The report also highlights differences between the AJCC 6th and 7th editions for classifying prostate cancer stage.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Data from 18 Surveillance, Epidemiology, and End Results (SEER) Program population\u2010based registries (SEER\u201018) were analyzed for the years 2004\u20102010, which included 400,591 prostate cancer cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>CSv2 provides specificity with regard to the Gleason grading system by distinguishing between clinical and pathologic patterns and scores. The AJCC 7th edition incorporates prostate\u2010specific antigen values into staging, subdivides stage II into IIA and IIB, and reclassifies extraprostatic invasion with microscopic bladder neck invasion from T4 in the 6th edition to T3a; this latter change affected the AJCC stage of 283 cases in 2010. Of the 44,578 prostate cancer cases diagnosed in 2010 that would have been classified as stage II in the AJCC 6th edition, 32.7%, 27.5%, and 39.8% are classified as stages I, IIA, and IIB, respectively, in the 7th edition.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>CSv2 provides more information than was previously available to researchers using SEER prostate data. The absence of a clearly defined clinical stage for each prostate case is the overriding limitation that researchers face in relying on Collaborative Stage information to analyze prostate cancer data. <jats:bold><jats:italic>Cancer<\/jats:italic> 2014;120(23 suppl):3758\u201070.<\/jats:bold> \u00a9 <jats:italic>2014 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.29052","type":"journal-article","created":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T09:39:19Z","timestamp":1416476359000},"page":"3758-3770","source":"Crossref","is-referenced-by-count":25,"title":["Prostate cancer collaborative stage data items\u2014their definitions, quality, usage, and clinical implications: A review of SEER data for 2004\u20102010"],"prefix":"10.1002","volume":"120","author":[{"given":"Maria J.","family":"Schymura","sequence":"first","affiliation":[{"name":"New York State Cancer Registry Division of Chronic Disease Prevention, New York State Department of Health Albany New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leon","family":"Sun","sequence":"additional","affiliation":[{"name":"Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute Bethesda Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoinette","family":"Percy\u2010Laurry","sequence":"additional","affiliation":[{"name":"Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute Bethesda Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,11,20]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"American Cancer Society. Cancer Facts & Figures 2014. American Cancer Society. Available at:http:\/\/www.cancer.org\/research\/cancerfactsstatistics\/cancerfactsfigures2014. Accessed on October 3 2014."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs491"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.12.1017"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-88441-7"},{"key":"e_1_2_7_6_1","first-page":"109","volume-title":"Collaborative Stage Data Collection System User Documentation and Coding Instructions","author":"Collaborative Stage Work Group of the American Joint Committee on Cancer","year":"2011"},{"key":"e_1_2_7_7_1","unstructured":"American College of Surgeons Commission on Cancer. Facility Oncology Registry Data Standards: Revised for 2007 (FORDS). American College of Surgeons Commission on Cancer; 2002 (updated 2007). Available at:http:\/\/www.facs.org\/cancer\/coc\/fords\/2007\/fordsrevised2007.pdf. Accessed August 21 2013."},{"key":"e_1_2_7_8_1","unstructured":"Surveillance Epidemiology and End Results (SEER) Program. SEER Site recode. Available at:http:\/\/seer.cancer.gov\/siterecode\/icdo3_d01272003\/. Accessed August 6 2013."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3656-4"},{"key":"e_1_2_7_10_1","first-page":"C551","volume-title":"SEER Program Coding and Staging Manual 2004","author":"Johnson CH","year":"2004"},{"key":"e_1_2_7_11_1","volume-title":"The SEER Program Code Manual","author":"Fritz A","year":"2013"},{"key":"e_1_2_7_12_1","unstructured":"Collaborative Stage Data Collection System Version 2. Prostate C61.9. Available at:http:\/\/web2.facs.org\/cstage0204\/prostate\/Prostateschema.html. Accessed August 6 2013."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.03.003"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.11.023"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.03.043"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2011.04003.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.13.1533"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.11.969"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.08.055"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.11.061"},{"key":"e_1_2_7_21_1","volume-title":"NCCN clinical practice guidelines in oncology: prostate cancer. Version 2.2013","author":"National Comprehensive Cancer Network","year":"2013"},{"key":"e_1_2_7_22_1","unstructured":"Surveillance Epidemiology and End Results (SEER) Program (http:\/\/www.seer.cancer.gov) SEER*Stat Database: Incidence \u2014 SEER 18 Regs Research Data\u2009+\u2009Hurricane Katrina Impacted Louisiana Cases Nov 2012 Sub (1973\u20102010 varying) \u2014 Linked to County Attributes \u2014 Total U.S. 1969\u20102011 Counties National Cancer Institute DCCPS Surveillance Research Program Surveillance Systems Branch released April 2013 based on the November 2012 submission."},{"key":"e_1_2_7_23_1","unstructured":"Collaborative Stage Version 2 Field Study Team. 2011 CSV2 Reliability Study Final Report. Available at:http:\/\/cancerstaging.org\/sites\/csqatest\/about\/news\/Pages\/CSv02.05\u2010Reliability\u2010Study\u2010Final\u2010Report\u2010.aspx. Accessed January 8 2014."},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.04.079"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.07.093"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031918"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.1.66"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-2-201207170-00459"},{"key":"e_1_2_7_29_1","unstructured":"AsireA LylesB CiceroBJ et al. The SEER Program Code Manual. 1988:80. Available at:http:\/\/seer.cancer.gov\/manuals\/historic\/codeman_1988.pdf. Accessed August 9 2013."},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000173646.99337.b1"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.11.009"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj190"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.02.072"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.29052","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.29052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:28:44Z","timestamp":1760275724000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.29052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,20]]},"references-count":32,"journal-issue":{"issue":"S23","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1002\/cncr.29052"],"URL":"https:\/\/doi.org\/10.1002\/cncr.29052","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,20]]}}}